1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Motherisk Update 2014
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting,
Details to be announced
- Read more in our News Archive
Current Studies at Motherisk
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy ForumArchived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
My husband is taking Mercaptopurine (Purinethol) to manage his Chrohn's disease. Can you please let me know if there is any risk involved to his sperm or the baby or if he should go off the drug if we are trying to get pregnant? Thanks
It has been shown that in male mice, mercaptopurine treatment may decrease sperm counts and fertility (Sykora I. Neoplasma 28:739-46, 1981: 26, Oakberg EF et al: Mutat res 94:165-78, 1982).
There is an inconclusive report on mercaptopurine use by men with inflammatory bowel disease concluded that use of the medication three months or less prior to conception produced an increase in adverse pregnancy outcome (Rajapakse RO, Korelitz BI, Zlantanic J, Baiocco PJ, Gleim GW. Am J Gastroenterol 2000;95:684-8.). This conclusion was based on 2 miscarriages and 2 pregnancies with birth defects occurring among 13 pregnancies fathered by men with recent mercaptopurine use compared to 1 miscarriage occurring among 37 control pregnancies fathered by men with more remote mercaptopurine use ( 3 months or greater). The birth defects consisted of thumb aplasia and growth retardation in one child and acrania with other limb malformations in an aborted fetus.
In general, there is no single example in humans of a cancer drug that has been shown to cause malformations through sperm exposure. However, cancer drugs do commonly decrease a man?s sperm count.